3-amino-biphenyl-2-carboxylic acid amide | 100723-85-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-amino-biphenyl-2-carboxylic acid amide
• 英文别名: 3-Amino-biphenyl-2-carbonsaeure-amid；3-aminobiphenyl-2-carboxamide；3-amino-2-carbamoylbiphenyl；2-amino-6-phenylbenzamide
• CAS: 100723-85-1
• 化学式: C₁₃H₁₂N₂O
• 分子量: 212.251
• InChiKey: YDHYSAGXZMGUQA-UHFFFAOYSA-N

物化性质

• 熔点：
  171 °C
• 沸点：
  396.8±35.0 °C(Predicted)
• 密度：
  1.208±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  69.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-amino-biphenyl-2-carboxylic acid amide 在 sodium methylate 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 31.0h， 生成 tert-butyl 4-(4-oxo-5-phenyl-3,4-dihydroquinazolin-2-yl)piperidine-1-carboxylate
  参考文献：
  名称：

  [EN] QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS
  [FR] QUINAZOLINES COMME INHIBITEURS DES CANAUX IONIQUES POTASSIQUES

  摘要：

  其中A、X、Y、Z、R1和R24如所述的(I)式化合物。这些化合物作为钾通道功能的抑制剂以及用于治疗和预防心律不齐、IKur相关疾病和其他由离子通道功能介导的疾病是有用的。

  公开号：

  WO2011028741A1
• 作为产物：
  描述：

  3-nitro-biphenyl-2-carbonitrile 在 盐酸 、 乙醇 、 tin(ll) chloride 作用下， 生成 3-amino-biphenyl-2-carboxylic acid amide
  参考文献：
  名称：

  573.合成一些苯基-cinnolines，-phthalazines和-quinoxalines

  摘要：

  DOI：

  10.1039/jr9590002858

文献信息

• Gastrin releasing peptide compounds
  申请人：——

  公开号：US20040253225A1

  公开（公告）日：2004-12-16

  New and improved compounds for use in diagnostic imaging or therapy having the formula M-N—O—P-G, wherein M is an optical label or a metal chelator (in the form complexed with a metal radionuclide or not), N—O—P is the linker, and G is the GRP receptor targeting peptide. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.

  本发明提供了用于诊断成像或治疗的新型化合物，其化学式为M-N—O—P-G，其中M是光学标记物或金属螯合剂（形式上与金属放射性核素络合或未络合），N—O—P是连接剂，G是GRP受体靶向肽。本发明还提供了使用该化合物对患者进行成像和/或提供放射治疗或光治疗的方法。还提供了制备诊断成像剂的方法和试剂盒。还提供了制备放射治疗剂的方法和试剂盒。
• Gastrin Releasing Peptide Compounds
  申请人：Cappelletti Enrico

  公开号：US20080008649A1

  公开（公告）日：2008-01-10

  New and improved compounds for use in diagnostic imaging or therapy having the formula M-N—O—P-G, wherein M is a metal chelator having the structure: wherein R 1 -R 5 and FG are as defined herein (in the form complexed with a metal radionuclide or not), N—O—P is the linker containing at least one non-alpha amino acid with a cyclic group, at least one substituted bile acid or at least one non-alpha amino acid, and G is the GRP receptor targeting peptide. In the preferred embodiment, M is an Aazta metal chelator or a derivative thereof. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided. Novel methods of treating prostate tumors or of delaying the progression of prostate tumors are also provided, including, methods of treating bone or soft tissue metastases of prostate cancer, methods for treating hormone sensitive and hormone refractory prostate cancer, methods for delaying the progression of hormone sensitive prostate cancer, for facilitating combination therapy in patients with hormone sensitive prostate cancer and for decreasing aberrant vascular permeability in patients with hormone sensitive prostate cancer.

  新的和改进的化合物可用于诊断成像或治疗，其化学式为M-N—O—P-G，其中M是具有以下结构的金属螯合剂： 其中R1-R5和FG如此定义（以金属放射性核素或未配合的形式），N—O—P是含有至少一个非α氨基酸环状基团、至少一个取代胆酸或至少一个非α氨基酸的连接物，而G是GRP受体靶向肽。在首选实施例中，M是Aazta金属螯合剂或其衍生物。本发明还提供了使用该化合物对患者进行成像和/或提供放射治疗或光治疗的方法。还提供了制备诊断成像试剂的方法和试剂盒。还提供了制备放射治疗试剂的方法和试剂盒。还提供了治疗前列腺肿瘤或延缓前列腺肿瘤进展的新方法，包括治疗前列腺癌骨骼或软组织转移的方法，治疗激素敏感和激素难治性前列腺癌的方法，延缓激素敏感前列腺癌进展的方法，促进激素敏感前列腺癌患者联合治疗的方法以及降低激素敏感前列腺癌患者异常血管渗透性的方法。
• METHOD FOR PRODUCING BIARYL COMPOUND
  申请人：Sato Koichi

  公开号：US20100087680A1

  公开（公告）日：2010-04-08

  A method for producing a biaryl compound, comprising reacting an aromatic organic compound with at least one compound selected from the group consisting of aromatic organoboron compounds and boroxine compounds, in the presence of a zero-valent nickel catalyst, phosphine ligand and base.

  一种制备双芳基化合物的方法，包括在零价镍催化剂、膦配体和碱的存在下，将芳香有机化合物与选自芳香基有机硼化合物和硼氧化物化合物组的至少一种化合物反应。
• GASTRIN RELEASING PEPTIDE COMPOUNDS
  申请人：Cappelletti Enrico

  公开号：US20110052491A1

  公开（公告）日：2011-03-03

  New and improved compounds for use in diagnostic imaging or therapy having the formula M—N—O—P—G, wherein M is an optical label or a metal chelator (in the form complexed with a metal radionuclide or not), N—O—P is the linker, and G is the GRP receptor targeting peptide. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.

  本发明涉及用于诊断成像或治疗的新型化合物，其化学式为M—N—O—P—G，其中M是光学标记或金属螯合剂（以与金属放射性核素形成络合物或非络合形式存在），N—O—P是连接剂，G是GRP受体靶向肽。本发明还提供了使用该化合物进行患者成像和/或提供放射治疗或光疗的方法。本发明还提供了制备诊断成像剂的方法和试剂盒。本发明还提供了制备放射治疗剂的方法和试剂盒。
• QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：US20140031345A1

  公开（公告）日：2014-01-30

  A compound of formula I wherein A, X, Y, Z, R 1 and R 24 are described herein. The compounds are useful as inhibitors of potassium channel function and in the treatment and prevention of arrhythmia, I Kur -associated disorders, and other disorders mediated by ion channel function.

  化合物I的化学式如下，其中A，X，Y，Z，R1和R24的描述在此处。这些化合物可用作钾通道功能的抑制剂，并用于治疗和预防心律失常，IKur相关疾病以及其他离子通道功能介导的疾病。